Scoop: Ab­b­Vie ter­mi­nates ear­ly-stage study of I-Mab's an­ti­body, an­oth­er clin­i­cal set­back in CD47 field

The CD47 field faced set­backs ear­li­er this year when Gilead’s ma­grolimab was hit with par­tial clin­i­cal holds, and an­oth­er clin­i­cal hur­dle can be added to the list, with Ab­b­Vie ter­mi­nat­ing a study of an an­ti­body out of part­ner I-Mab.

The nixed study was ex­plor­ing the IV drug lem­zopar­limab in com­bi­na­tion with or with­out an oral or IV for­mu­la­tion of dex­am­etha­sone and in com­bi­na­tion with an­ti-myelo­ma reg­i­mens in adults with mul­ti­ple myelo­ma. The tri­al be­gan in Jan­u­ary and had been slat­ed for a Ju­ly 2025 com­ple­tion, but Ab­b­Vie end­ed up on­ly en­rolling eight pa­tients with the white blood cell can­cer out of an orig­i­nal­ly planned 163, ac­cord­ing to the fed­er­al tri­als data­base.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.